title: [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
abstract: Sulphasalazine (SASP) is the drug of choice in the treatment of ulcerative colitis (UC). But there are adverse effects in 20-30% dependent on the serum-level of the resorbed SASP-metabolite sulphapyridine (SP). Relapses during treatment may have their cause in an under-dosage or patient's non-compliance. In 19 patients with UC the possibility of an individualized most effective treatment and the patient's compliance by the simple practicable analysis of SP-serum-level were checked. The results show that it is necessary to dose the SASP in dependence of the genetically determined type of acetylation. The SASP-dosage must be decreased in patients with slow acetylation and vice versa consequently. After rectal SASP-application - in opposite to the oral treatment - significant lower serum levels of SP were analyzed. In 63.1% of the patients we found an insufficient of non-compliance.
authors.affiliation: Fachkrankenhaus für Innere Medizin, Leipzig, DDR.
authors.forename: H J
authors.initials: HJ
authors.lastname: Klugmann
authors.forename: B
authors.initials: B
authors.lastname: Giehler
authors.forename: D
authors.initials: D
authors.lastname: Lohmann
authors.forename: W
authors.initials: W
authors.lastname: Schiedewitz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013424:Sulfanilamides / Q000493:pharmacokinetics*; D013427:Sulfapyridine / Q000493:pharmacokinetics*; D012460:Sulfasalazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013488:Suppositories
chemical_list: D013424:Sulfanilamides; D013488:Suppositories; D012460:Sulfasalazine; D013427:Sulfapyridine
vernacular_title: Individuelle Sulfasalazin-Therapie der Colitis ulcerosa und Uberwachung der Patienten-Compliance durch Serumkonzentrationsbestimmung des Sulfapyridin.